Eli Lilly and Company
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.97B | $21.22B | $19.96B | $19.61B | $23.11B | $22.60B | $24.29B | $23.08B |
| Zyprexa | — | $816.3M | $1.04B | $1.04B | $1.17B | $1.70B | $4.62B | $5.03B |
| Cialis | — | $2.47B | $2.31B | $2.29B | $2.16B | $1.93B | $1.88B | $1.70B |
| Alimta | — | $2.16B | $2.47B | $1.80B | $2.70B | $2.59B | $2.46B | $2.21B |
| Humalog | — | $2.84B | $2.84B | $2.79B | $2.61B | $2.40B | $2.38B | $2.05B |
| Humulin | — | $1.28B | $1.31B | $1.40B | $1.41B | $1.32B | $1.26B | $1.09B |
| Gemzar | — | $0 | $0 | $0 | $283.7M | $361.3M | $498.4M | $1.15B |
| Evista | — | $0 | $0 | $419.6M | $1.05B | $1.01B | $1.07B | $1.03B |
| Forteo | — | $1.50B | $1.35B | $1.32B | $1.24B | $1.15B | $949.7M | $816.7M |
| Strattera | — | $752.4M | $784.0M | $731.4M | $708.2M | $620.0M | $619.6M | $609.4M |
| Symbyax | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Erbitux | — | $687.2M | $683.3M | $0 | $0 | $0 | $0 | $0 |
| Byetta | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Trad jenta | — | $457.6M | $429.6M | $622.3M | $480.9M | $248.8M | $114.7M | $0 |
| Effient | — | $509.3M | $518.5M | $522.6M | $508.8M | $452.3M | $302.7M | $114.3M |
| Jardiance | — | $285.9M | $85.6M | $47.4M | $0 | $0 | $0 | $0 |
| Trulicity | — | $925.7M | $248.3M | $19.0M | $0 | $0 | $0 | $0 |
| Taltz | — | $113.1M | $0 | $0 | $0 | $0 | $0 | $0 |
| Olumiant | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Verzenio | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Emgality | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Tyvyt | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cyramza | — | $614.1M | $384.3M | $28.4M | $0 | $0 | $0 | $0 |
| Baqsimi | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Retevmo | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Bebtelovimab | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Mounjaro | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Jaypirca | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Zepbound | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Omvoh | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Ebglyss | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Kisunla | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Animal Health | — | $3.16B | $3.18B | $2.35B | $2.15B | $2.04B | $1.68B | $1.39B |
| Collaboration and Other Revenue | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Pharmaceutical Products | — | $2.62B | $2.32B | $4.24B | $6.64B | $4.78B | $6.48B | $5.89B |
| Cost of Revenue | $4.45B | $5.71B | $5.04B | $4.93B | $4.91B | $4.80B | $5.07B | $4.37B |
| Gross Profit | $15.53B | $15.51B | $14.92B | $14.68B | $18.20B | $17.80B | $19.22B | $18.71B |
| Gross Margin | 77.7% | 73.1% | 74.8% | 74.9% | 78.8% | 78.8% | 79.1% | 81.1% |
| Operating Expenses | ||||||||
| Research & Development | $5.10B | $5.31B | $4.80B | $4.73B | $5.53B | $5.28B | $5.02B | $4.88B |
| SG&A Expense | $5.98B | $6.53B | $6.53B | $6.62B | $7.13B | $7.51B | $7.88B | $7.05B |
| Operating Income | $2.53B | $3.56B | $2.95B | $3.15B | $6.05B | $5.08B | $6.32B | $6.95B |
| Operating Margin | 12.7% | 16.8% | 14.8% | 16.1% | 26.2% | 22.5% | 26.0% | 30.1% |
| Interest Expense | $225.0M | $185.2M | $161.2M | $148.8M | $160.1M | $177.8M | $186.0M | $185.5M |
| Pretax Income | $2.30B | $3.37B | $2.79B | $3.00B | $5.89B | $4.90B | $6.14B | $6.77B |
| Income Tax Expense | $2.39B | $636.4M | $381.6M | $609.8M | $1.20B | $1.32B | $1.00B | $1.46B |
| Net Income | $-204.1M | $2.74B | $2.41B | $2.39B | $4.68B | $4.09B | $4.35B | $5.07B |
| Net Margin | -1.0% | 12.9% | 12.1% | 12.2% | 20.3% | 18.1% | 17.9% | 22.0% |
| EPS (Basic) | $-0.19 | $2.59 | $2.27 | $2.23 | $4.33 | $3.67 | $3.90 | $4.58 |
| EPS (Diluted) | $-0.19 | $2.58 | $2.26 | $2.23 | $4.32 | $3.66 | $3.90 | $4.58 |
| Shares Outstanding (Basic) | 1.05B | 1.06B | 1.06B | 1.07B | 1.08B | 1.11B | 1.11B | 1.11B |
| Shares Outstanding (Diluted) | 1.05B | 1.06B | 1.07B | 1.07B | 1.08B | 1.12B | 1.11B | 1.11B |
| Dividends Per Share | $2.12 | $2.05 | — | — | — | — | $1.96 | $1.96 |